1.1 Background In the past decade, the evaluation and management of patients with VHD
has changed dramatically. Advances in noninvasive imaging have enabled reliable …

Heart disease is the leading cause of death in the United States (1), and coronary artery
disease is the most common type of heart disease (2). The annual estimated cost of heart …

The “Guidelines on the Management of Valvular Heart Disease” were initially published as
the “Guidelines on Non-pharmacological Treatment of Valvular Heart Disease” in 2002 …

Aims We sought to evaluate the outcomes of transcatheter mitral valve replacement (TMVR)
for patients with degenerated bioprostheses [valve-in-valve (ViV)], failed annuloplasty rings …

Importance Early surgery for severe primary degenerative mitral regurgitation is
recommended, provided optimal outcomes are achievable. Contemporary national data …

Background Risk estimation for surgical intervention is an essential component of heart
team shared decision-making. However, current mitral valve (MV) surgery risk models used …

As transcatheter aortic valve replacement becomes a more dominant treatment option
across all risk profiles, the frequency of encountering patients with multivalvular disease will …

Myocardial injury is a common complication of the COVID-19 illness and is associated with a
worsened prognosis. Systemic hyperinflammation seen in the advanced stage of COVID-19 …

Background: Diverging guideline definitions for the quantitative assessment of severe
secondary mitral regurgitation (sMR) reflect the lacking link of the sMR spectrum to mortality …

Structural heart disease (SHD) is at the cutting edge of innovation in cardiovascular disease
with a focus on the importance of the “heart team”(1, 2). Development of the heart team, with …